yeah...with the KITE deal it appears that CAR-T is being considered a viable technology. How to handicap the different players is another question. If CLLS can provide clinical data showing their CAR-T process also is viable, what would their value be?
“A bank would never get away with what the Department of Education is doing.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.